Novo Nordisk files annual report with the SEC

| Source: Novo Nordisk A/S Novo Nordisk A/S

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at novonordisk.com/investors/download-centre or upon request to either tel no +1 (609) 712-8127 or by e-mail to cqfr@novonordisk.com. When e-mailing, please state the exact mailing address and the document(s) you wish to receive.
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
Further information: